Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

$Clinical benefit with SGLT inhibitor in diabetes patients with HF independent of ejection fraction$ $Clinical benefit with SGLT inhibitor in diabetes patients with HF independent of ejection fraction$
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
ACC.19
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
- Dr. Eri Kato
No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients
No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients
ACC.19
No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients
Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF
Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF
ACC.19
Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF
Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis
Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis
ACC.19
Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis